Importer of Controlled Substances; Notice of Application, 69460-69461 [2010-28529]
Download as PDF
<![CDATA[
69460
Federal Register / Vol. 75, No. 218 / Friday, November 12, 2010 / Notices
Drug
Schedule
mstockstill on DSKH9S0YB1PROD with NOTICES
5-Methoxy-N,N-diisopropyltryptamine (7439) ..............................................................................................................................................
N-Benzylpiperazine (7493) ..........................................................................................................................................................................
Etorphine (except HCl) (9056) ....................................................................................................................................................................
Heroin (9200) ...............................................................................................................................................................................................
Morphine-N-oxide (9307) .............................................................................................................................................................................
Normorphine (9313) ....................................................................................................................................................................................
Pholcodine (9314) .......................................................................................................................................................................................
Dextromoramide (9613) ...............................................................................................................................................................................
Dipipanone (9622) .......................................................................................................................................................................................
Racemoramide (9645) .................................................................................................................................................................................
Trimeperidine (9646) ...................................................................................................................................................................................
Tilidine (9750) ..............................................................................................................................................................................................
Amphetamine (1100) ...................................................................................................................................................................................
Methamphetamine (1105) ...........................................................................................................................................................................
Methylphenidate (1724) ...............................................................................................................................................................................
Amobarbital (2125) ......................................................................................................................................................................................
Pentobarbital (2270) ....................................................................................................................................................................................
Secobarbital (2315) .....................................................................................................................................................................................
Phencyclidine (7471) ...................................................................................................................................................................................
Phenylacetone (8501) .................................................................................................................................................................................
Cocaine (9041) ............................................................................................................................................................................................
Codeine (9050) ............................................................................................................................................................................................
Dihydrocodeine (9120) ................................................................................................................................................................................
Oxycodone (9143) .......................................................................................................................................................................................
Hydromorphone (9150) ...............................................................................................................................................................................
Benzoylecgonine (9180) ..............................................................................................................................................................................
Ethylmorphine (9190) ..................................................................................................................................................................................
Meperidine (9230) .......................................................................................................................................................................................
Methadone (9250) .......................................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) (9273) ..............................................................................................................................
Morphine (9300) ..........................................................................................................................................................................................
Oripavine (9330) ..........................................................................................................................................................................................
Thebaine (9333) ..........................................................................................................................................................................................
Levo-alphacetylmethadol (9648) .................................................................................................................................................................
Oxymorphone (9652) ...................................................................................................................................................................................
Poppy Straw Concentrate (9670) ................................................................................................................................................................
Fentanyl (9801).
The company plans to import small
quantities of the listed controlled
substances for the manufacture of
analytical reference standards.
No comments, objections, or requests
for any hearings will be accepted on any
application for registration or reregistration to import crude opium,
poppy straw, concentrate of poppy
straw, and coca leaves. As explained in
the Correction to Notice of Application
pertaining to Rhodes Technologies, 72
FR 3417 (2007), comments and requests
for hearings on applications to import
narcotic raw material are not
appropriate.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act [(21 U.S.C. 952
(a)(2)(B)] may, in the circumstances set
forth in 21 U.S.C. 958(i), file comments
or objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR § 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
VerDate Mar<15>2010
17:23 Nov 10, 2010
Jkt 223001
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 13, 2010.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Dated: November 1, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–28519 Filed 11–10–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on
September 14, 2010, GE Healthcare,
3350 North Ridge Avenue, Arlington
E:\FR\FM\12NON1.SGM
12NON1
69461
Federal Register / Vol. 75, No. 218 / Friday, November 12, 2010 / Notices
Heights, Illinois 60004–1412, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of Cocaine
(9041), a basic class of controlled
substance listed in schedule II.
The company plans to import small
quantities of ioflupane, in the form of
three separate analogues of Cocaine, to
validate production and quality control
systems, for a reference standard, and
for producing material for a future
investigational new drug (IND)
submission.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 13, 2010.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: November 1, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–28529 Filed 11–10–10; 8:45 am]
mstockstill on DSKH9S0YB1PROD with NOTICES
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Dated: November 1, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
VerDate Mar<15>2010
17:23 Nov 10, 2010
Jkt 223001
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on June
28, 2010, Wildlife Laboratories, 1401
Duff Drive, Suite 400, Fort Collins,
Colorado 80524, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Etorphine Hydrochloride
(9059), a basic class of controlled
substance listed in schedule II.
The company plans to import the
listed controlled substance for sale to its
customer.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration,
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 13, 2010.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
[FR Doc. 2010–28526 Filed 11–10–10; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated June 17, 2010, and
published in the Federal Register on
June 28, 2010 (75 FR 36684), Cerilliant
Corporation, 811 Paloma Drive, Suite A,
Round Rock, Texas 78665–2402, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
classes of controlled substances listed in
schedule I:
Drug
Racemoramide (9645) ..................
Tilidine (9750) ...............................
Schedule
I
I
The company plans to import small
quantities of the listed controlled
substances for the manufacture of
analytical reference standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Cerilliant Corporation to import the
basic classes of controlled substances is
consistent with the public interest, and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Cerilliant Corporation
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: November 1, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–28523 Filed 11–10–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated August 13, 2010, and
published in the Federal Register on
E:\FR\FM\12NON1.SGM
12NON1
]]>Agencies
[Federal Register Volume 75, Number 218 (Friday, November 12, 2010)]
[Notices]
[Pages 69460-69461]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-28529]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on September 14, 2010, GE Healthcare, 3350 North Ridge Avenue,
Arlington
[[Page 69461]]
Heights, Illinois 60004-1412, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as an importer of
Cocaine (9041), a basic class of controlled substance listed in
schedule II.
The company plans to import small quantities of ioflupane, in the
form of three separate analogues of Cocaine, to validate production and
quality control systems, for a reference standard, and for producing
material for a future investigational new drug (IND) submission.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43 and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than December 13, 2010.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, (40 FR 43745-46), all
applicants for registration to import a basic class of any controlled
substance in schedule I or II are, and will continue to be, required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: November 1, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2010-28529 Filed 11-10-10; 8:45 am]
BILLING CODE 4410-09-P
